Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia.
Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia.
复制标题
干扰素α-2b治疗毛细胞白血病的成本效益分析。
DOI：
10.1093/jnci/81.8.594
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Spiegel,RJ
中科院分区：
文献类型：
--
作者：
Ozer,H;Golomb,HM;Zimmerman,H;Spiegel,RJ
基于128例使用重组干扰素(IFN) α -2b治疗进行性毛细胞白血病的12个月临床数据，回顾性评估了使用重组干扰素(IFN) α -2b替代传统化疗（主要是氯霉素）的临床获益和成本效益。71例既往接受常规治疗的对照患者的数据用于生存分析。血液反应（细胞减少的逆转）在对照组患者中达到18%，而在wn治疗的患者中达到73%。这种反应与几乎无需输血和脾切除术以及致命感染频率（22.5%对1.6%）和12个月死亡率（28%对3.1%）的显著降低有关。接受WN α -2b治疗的患者每年医疗护理（输血、抗生素治疗、脾切除术和化疗）的人均直接费用比对照组患者低2.8倍（5027美元对14046美元）。间接成本（反映因过早死亡而损失的未来收入的现值）在接受神经性神经病变治疗的患者中比对照组低13.3倍（分别为4771美元和63,507美元）。我们的分析表明，IFN α -2b为毛细胞白血病患者提供了实质性的临床和成本优势，并且采用新型生物技术引入这种疗法进一步促进了卫生保健界对成本控制的承诺。[J]中华癌症杂志（英文版），2009。
The clinical benefits as well as the cost benefits of use of recombinant interferon (IFN) alfa-2b instead of conventional chemotherapy (primarily chlorambucil) for progressive hairy cell leukemia were assessed retrospectively on the basis of 12 months of clinical data from 128 patients treated with WN alfa-2b. Data from 71 matched historical control patients who had received conventional treatment were used for survival analysis. Hematologic response (reversal of cytopenias) was achieved by 18% of the control patients versus 73% of the WN-treated patients. This response was associated with virtual elimination of the need for transfusions and splenectomy as well as dramatic decreases In the frequency of fatal infections (22.5% vs. 1.6%) and the 12-month mortality rate (28% vs. 3.1%). Direct costs per patient per year for medical care (transfusions, antibiotic treatment, splenec Receivedtomy, and chemotherapy) of those receiving WN alfa-2b were 2.8-fold lower than costs for medical care of control patients ($5,027 vs. $14,046). Indirect costs, which reflect the present value of future earnings lost due to premature death, were 13.3-fold lower for WN-treated patients than for control patients ($4,771 vs. $63,507). Our analysis demonstrates that IFN alfa-2b offers substantial clinical and cost advantages to patients with hairy cell leukemia and that the introduction of this therapy using novel biotechnology furthers the health care community's commitment to cost containment. [J Natl Cancer Inst 81:594–602, 1989]